Q-omics provides the consensus-scored ZNF559-ZNF177 profile across patient tissues and cancer cell-line models. ZNF559-ZNF177 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ZNF559-ZNF177 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ZNF559-ZNF177 RNA expression shows 20,936 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KIRC, and THYM as cancer lineages where ZNF559-ZNF177 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF559-ZNF177 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF559-ZNF177 survival associations across molecular data types. ZNF559-ZNF177 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF559-ZNF177 RNA expression–survival associations across cancer types. High ZNF559-ZNF177 expression shows unfavorable associations in SCLC and LUSC, but favorable associations in BLCA, LUAD, UCS and ACC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ZNF559-ZNF177 RNA expression.
This table summarizes ZNF559-ZNF177 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF559-ZNF177. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF559-ZNF177 shows lower tumor expression in KIRC, UCEC and THCA and higher tumor expression in LIHC, HNSC and CHOL. The KIRC box plot shows higher ZNF559-ZNF177 RNA expression in normal versus tumor tissue (log2 FC = −0.168, t-test p < 0.001).
This table shows molecular features associated with ZNF559-ZNF177 in patient tissues and cancer cell lines. In patient samples, ZNF559-ZNF177 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
